This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Diederichs, S. Articles by Haber, D. A. Search for Related Content PubMed PubMed Citation Articles by Diederichs, S. Articles by Haber, D. A.

Sequence Variations of MicroRNAs in Human Cancer: Alterations in Predicted Secondary Structure Do Not Affect Processing

Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts

Requests for reprints: Daniel Haber, Massachusetts General Hospital Cancer Center, Harvard Medical School, Building 149, 13th Street, Charlestown, MA 02129. Phone: 617-726-7805; Fax: 617-724-6919; E-mail: haber{at}helix.mgh.harvard.edu.

Expression levels of microRNAs (miRNAs) are globally reduced in cancer compared with matched normal tissues, and miRNA function has recently been implicated in tumorigenesis. To test whether epigenetic silencing contributes to miRNA suppression in tumors, lung cancer cells were treated with inhibitors of DNA methylation or histone deacetylation. No significant alteration in miRNA expression was detected using microarray profiling. To search for tumor-associated mutations that could affect processing and expression of mature miRNAs, a panel of 91 cancer-derived cell lines was analyzed for sequence variations in 15 miRNAs implicated in tumorigenesis by virtue of their known target transcripts (let-7 family targeting oncogenic Ras) or their localization to sites of frequent chromosomal instability (miR-143, miR-145, miR-26a-1, and miR-21). No mutations were detected within any of the short mature miRNA sequences. In addition to previously reported polymorphisms, 1 sequence variant in a precursor miRNA and 15 variants in primary miRNA (pri-miRNA) transcripts were identified. Despite pri-miRNAs having dramatic changes in the predicted secondary folding structure flanking putative cleavage sites, processing and miRNA maturation were not affected in vivo. Thus, genetic variants in miRNA precursors are common in cancer cells but are unlikely to have physiologic significance. (Cancer Res 2006; 66(12): 6097-104)

This article has been cited by other articles:

				N. S. Wickramasinghe, T. T. Manavalan, S. M. Dougherty, K. A. Riggs, Y. Li, and C. M. Klinge Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells Nucleic Acids Res., May 1, 2009; 37(8): 2584 - 2595. [Abstract] [Full Text] [PDF]

				X. Liu, L. F. Sempere, F. Galimberti, S. J. Freemantle, C. Black, K. H. Dragnev, Y. Ma, S. Fiering, V. Memoli, H. Li, et al. Uncovering Growth-Suppressive MicroRNAs in Lung Cancer Clin. Cancer Res., February 15, 2009; 15(4): 1177 - 1183. [Abstract] [Full Text] [PDF]

				Y. Horikawa, C. G. Wood, H. Yang, H. Zhao, Y. Ye, J. Gu, J. Lin, T. Habuchi, and X. Wu Single Nucleotide Polymorphisms of microRNA Machinery Genes Modify the Risk of Renal Cell Carcinoma Clin. Cancer Res., December 1, 2008; 14(23): 7956 - 7962. [Abstract] [Full Text] [PDF]

				J. L. Bearfoot, D. Y.H. Choong, K. L. Gorringe, and I. G. Campbell Genetic Analysis of Cancer-Implicated MicroRNA in Ovarian Cancer Clin. Cancer Res., November 15, 2008; 14(22): 7246 - 7250. [Abstract] [Full Text] [PDF]

				Y. Ye, K. K. Wang, J. Gu, H. Yang, J. Lin, J. A. Ajani, and X. Wu Genetic Variations in MicroRNA-Related Genes Are Novel Susceptibility Loci for Esophageal Cancer Risk Cancer Prevention Research, November 1, 2008; 1(6): 460 - 469. [Abstract] [Full Text] [PDF]

				M. Wu, N. Jolicoeur, Z. Li, L. Zhang, Y. Fortin, D. L'Abbe, Z. Yu, and S.-H. Shen Genetic variations of microRNAs in human cancer and their effects on the expression of miRNAs Carcinogenesis, September 1, 2008; 29(9): 1710 - 1716. [Abstract] [Full Text] [PDF]

				S. Diederichs, S. Jung, S. M. Rothenberg, G. A. Smolen, B. G. Mlody, and D. A. Haber Coexpression of Argonaute-2 enhances RNA interference toward perfect match binding sites PNAS, July 8, 2008; 105(27): 9284 - 9289. [Abstract] [Full Text] [PDF]

				H. Yang, C. P. Dinney, Y. Ye, Y. Zhu, H. B. Grossman, and X. Wu Evaluation of Genetic Variants in MicroRNA-Related Genes and Risk of Bladder Cancer Cancer Res., April 1, 2008; 68(7): 2530 - 2537. [Abstract] [Full Text] [PDF]

				L. T. Bemis, R. Chen, C. M. Amato, E. H. Classen, S. E. Robinson, D. G. Coffey, P. F. Erickson, Y. G. Shellman, and W. A. Robinson MicroRNA-137 Targets Microphthalmia-Associated Transcription Factor in Melanoma Cell Lines Cancer Res., March 1, 2008; 68(5): 1362 - 1368. [Abstract] [Full Text] [PDF]

				W. Zhang, J. E. Dahlberg, and W. Tam MicroRNAs in Tumorigenesis: A Primer Am. J. Pathol., September 1, 2007; 171(3): 728 - 738. [Abstract] [Full Text] [PDF]

				C. Blenkiron and E. A. Miska miRNAs in cancer: approaches, aetiology, diagnostics and therapy Hum. Mol. Genet., April 15, 2007; 16(R1): R106 - R113. [Abstract] [Full Text] [PDF]